2017
A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis
Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00498-16. PMID: 27956422, PMCID: PMC5328532, DOI: 10.1128/aac.00498-16.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsBayes TheoremBiological AvailabilityComputer SimulationDrug Administration ScheduleDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFluoroquinolonesHumansMicrobial Sensitivity TestsModels, StatisticalMycobacterium tuberculosisPyrazinamideRifampinTuberculosis, PulmonaryConceptsCompanion drugsExtensively Drug-Resistant TuberculosisSecond-line treatmentFirst-line treatmentSecond-line regimensDrug-resistant tuberculosisUse of pyrazinamideExtensive drug resistanceDrug resistance dataEmergence of strainsEmergence of mutationsXDR-TBSequential regimensHIV infectionAlternative drugsResistance amplificationPyrazinamide resistanceProlonged treatmentCombination antimicrobialsDrug resistanceInfectious diseasesPrevalenceProportion of simulationsAppropriate useRegimens
2015
Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis
Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. The Lancet Respiratory Medicine 2015, 3: 963-972. PMID: 26597127, PMCID: PMC4684734, DOI: 10.1016/s2213-2600(15)00458-0.Peer-Reviewed Original ResearchConceptsMDR tuberculosisDynamic transmission modelPerson transmissionTuberculosis incidenceTuberculosis treatmentTuberculosis epidemicMDR tuberculosis casesDrug-susceptible tuberculosisFirst-line treatmentHigh-burden settingsMultidrug-resistant tuberculosisEpidemic of tuberculosisDrug regimensTuberculosis casesMDR prevalenceTuberculosis notificationsTuberculosis prevalenceNotification dataMDR acquisitionMDR transmissionTuberculosisMultidrug resistanceDe novo mutationsMelinda Gates FoundationNational Institute
2013
Cost-effectiveness of novel first-line treatment regimens for tuberculosis
Owens JP, Fofana MO, Dowdy DW. Cost-effectiveness of novel first-line treatment regimens for tuberculosis. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 590-596. PMID: 23575322, PMCID: PMC3844288, DOI: 10.5588/ijtld.12.0776.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsFirst-line treatmentStandard treatmentTotal disability-adjusted life yearsFailure/relapseShort-course regimensFirst-line regimensFirst-line drugsHigher drug costsHealth care perspectiveDrug pricesTB patientsActive tuberculosisNovel regimensPatient cohortDrug costsEqual efficacyRegimensLife yearsCare perspectiveTuberculosisRelapsePatientsTreatmentShort duration